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Background: Metabolic and cardiovascular side effects have been noted with the use of second generation
antipsychotics (SGAs) and mood stabilizers. Since Omega-3 fatty acids have been known to prevent some
cardiovascular risks, this preliminary study was designed to evaluate the cardiovascular benefits of omega-3 when
added to the combinations of olanzapine with mood stabilizers.
Methods: This study was a randomized, double-blind, placebo-controlled, within-subject trial in adult psychiatric
patients who were receiving olanzapine combined with lithium (Li) or valproate sodium (VPA). Omega-3 as fish oil
with less than 1 g/day of EPA/DHA or its placebo was added to patients’ olanzapine and mood stabilizer regimens
for 6 weeks. Metabolic parameters including anthropometric variables, lipid profile, metabolic syndrome indices,
C-reactive protein, fibrinogen and lipoprotein (a) [(Lp) (a)] were assessed for participants.
Results: Forty one participants completed this study; 20 patients received omega-3 and 21 patients received
placebo, added to their regimen of SGA and mood stabilizer. Omega-3 addition did not modulate anthropometric,
metabolic syndrome and lipid parameter changes in 6 weeks. However, fibrinogen levels significantly decreased, Lp
(a) did not increase and non-high-density lipoprotein cholesterol (non-HDL-C) did not go beyond its target level
after omega-3 supplementation. Additionally, a significant inter-group effect was noted for Lp(a).
Conclusions: This study suggests that use of short-term omega-3 supplementation added to a combined regimen
of olanzapine and mood stabilizer may have a small modulating effect on some cardiovascular risk factors. Trials in
longer periods of time and with larger number of patients are needed to further evaluate the effects of omega-3
supplements on preventing cardiovascular risk factors.
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Second generation antipsychotics (SGAs), in particular
clozapine and olanzapine have been linked to excessive
weight gain, dyslipidemia, hypertension and develop-
ment of metabolic syndrome (MetS) [1]. Weight gain is
also an unfavorable effect of valproate sodium (VPA)
and lithium (Li) [2]. Moreover, VPA has been reported
to be associated with dyslipidemia which is independent
of weight gain [3]. Psychiatric patients often receive
polypharmacy with antipsychotics and mood stabilizers
in real practice. It has been noted that patients on poly-
pharmacy regimens have a higher prevalence of meta-
bolic abnormalities [4,5] and more enhanced weight gain
[6].
Primary prevention of cardiovascular and metabolic
risk development has been suggested to offer the great-
est potential to reduce cardiovascular mortality in psy-
chiatric patients [7]. Therefore, it seems mandatory to
find safe preventive strategies to attenuate metabolic side
effects of psychiatric medications.
Omega-3 polyunsaturated fatty acids in forms of ei-
cosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) in fish oil have been found to correct several car-
diovascular risk factors [8–12]. Of note, it has been
demonstrated that EPA and DHA can decrease produc-
tion of inflammatory markers such as IL-1, IL-6 and
TNF-α [13]. This may explain the mechanism by which
omega-3 fatty acids could be useful in psychiatric
patients with a high risk of metabolic abnormalities.
Thus, this preliminary study was designed to evaluate
the effects of omega-3 supplements on preventing car-
diovascular risk factors by assessing changes in weight,
body mass index (BMI), waist circumference (WC),
blood pressure (BP) and lipid profiles in a group of psy-
chiatric patients who were on olanzapine plus Li or
olanzapine plus VPA for 6 weeks. Additionally, levels of
Lp(a), c-reactive protein, high sensitive (CRP-hs) and fi-
brinogen were also measured in order to explore other
cardiovascular risk factors and proinflammatory and
procoagulant states in the study subject.
Materials and methods
This clinical trial with an identifier number of
IRCT138712231764N1 was registered at irct.ir and was
conducted at Roozbeh hospital, affiliated with Tehran
University of Medical Sciences (TUMS). Patients be-
tween 18-60 years who were diagnosed with schizophre-
nia, bipolar I, or schizoaffective disorders according to
DSM-IV-TR criteria were included. Subjects were
included if they were on combination therapy of olanza-
pine plus VPA or olanzapine plus Li which was either
started simultaneously or the second drug was added
within the first 15 days of the initiation of the first medi-
cation. This time frame was chosen due to increasedprevalence of MetS in patients with bipolar disorder
who have been on medications for at least 3 weeks [14].
Exclusion criteria of the study included: (i) treatment
with study drugs (olanzapine, VPA, Li) during three
months prior to the trial initiation; (ii) any significant
medical problem or abnormal laboratory tests before
trial participation including: liver function tests ≥ 3 times
normal, thyroid stimulating hormone > 4.2 m.I.U/L,
GFR < 60 ml/min, fasting blood sugar (FBS) > 125 mg/dl,
TG ≥ 500 mg/dl, TG between 200-500 mg/dl with non-
high-density lipoprotein cholesterol (non-HDL-C)
greater than its target at the time of the study. Non-
HDL-C is determined as total cholesterol (TC) minus
HDL-C or as very low-density lipoprotein cholesterol
(VLDL-C) plus low density lipoprotein cholesterol
(LDL-C). It should be mentioned that non-HDL-C treat-
ment goals are defined according to The National Chol-
esterol Education Program (NCEP) Adult Treatment
Panel (ATP) III criteria [15]. Patients were categorized
based on a) suffering coronary heart disease (CHD) or
CHD risk equivalent, b) not having CHD but having
more than 2 risk factors, or c) not suffering CHD and
having fewer than 2 risk factors. Treatment goal for each
of the above categories if non-HDL-C is greater than
130 mg/dl, 160 mg/dl and 190 mg/dl, respectively); (iii)
pregnancy or breastfeeding; (iv) consumption of omega-
3 fatty acids recently (within 4 weeks prior to the study
initiation); (v) a BMI ≥ 30 kg/m2; (vi) any contraindica-
tion to receive study drugs; (vii) refusal to participate in
the study (by patients or their guardians); (viii) receiving
any drug(s), including statins, with much known effects
on study parameters; and (ix) a history of any drug or al-
cohol abuse/dependence within six months prior to the
initiation of the study.
The study was performed in accordance with the Dec-
laration of Helsinki and approved by the ethic commit-
tee of TUMS. Written informed consent was obtained.
Study design
This study was designed as a randomized, double-blind,
placebo-controlled, within-subject trial in which partici-
pants were assigned to receive either omega-3 (fish oil)
or placebo. Permuted block randomization table was
used and patients were stratified according to partici-
pant's smoking status and type of combination therapy
(olanzapine plus VPA or olanzapine plus Li). Participants
were given omega-3 or identical placebo capsules that
were provided by Zahravi Pharmaceutical Company
based in Tabriz, Iran for a total of 6 weeks. Each active
drug capsule contained 1000 mg omega-3 fatty acids
equivalent to 300 mg EPA/DHA. Omega-3 or placebo
capsules were titrated up starting with 1 capsule/day in
the first week, 2 capsules/day (twice daily) in the second
week and 3 capsules/day (in divided doses) from the
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utilized in this study is considered the dietary or low
dose supplementation (< 1 g/day EPA/DHA) [16].
Each patient was required to remain stable on his/her
combination therapy protocol throughout the course of
study (olanzapine plus Li or olanzapine plus VPA); how-
ever, dosage adjustment was permitted according to the
decisions of the treating psychiatrists. Mean olanzapine,
Li and VPA doses were recorded at the trial initiation,
during each week and at the end of the study. Other
medications that participants may have received at any
time during the trial were also recorded (this included
both prescription and over-the-counter medications).
Body weight (BW), height, waist circumference (WC)
and blood pressure (BP) as well as plasma levels of tri-
glyceride (TG), total cholesterol (TC), low density lipo-
protein (LDL), high density lipoprotein (HDL), Lp (a),
fibrinogen and CRP-hs were measured at baseline and at
week 6. Blood pressure was monitored using mercury
sphygmomanometer. BW and WC were assessed in the
morning before breakfast. BW was measured without
shoes on and in light clothing by a digital scale. WC was
determined by placing a measuring tape at the top of
right iliac crest and proceeding around the abdomen fol-
lowing normal expiration, ensuring that the tape is tight
but not constricting the skin. The "Quetelet Index", BMI
was calculated as weight in kilograms (kg) divided by
height square in meter square (m2). Blood samples were
taken between 8 to 9 a.m after a twelve hour overnight
fast. Serum TC, HDL, TG, and LDL were measured by6
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Statistical analysis
Statistical analysis was carried out with the SPSS statis-
tical package version 15. Demographic characteristics
are summarized descriptive and compared using chi-
square and independent sample t-test statistical method
for qualitative and quantitative data respectively. Base-
line characteristic in all variables were recorded prior
the study and compared using independent sample
t-test. Paired t test were carried out as within group
before-after comparison. Comparison of end point
changes from baseline was analyzed using within-
subjects effects of Repeated Measure ANOVA consider-
ing interaction of groups. All statistical significant tests
were 2-sided with a nominal significance level 0.05.
Results
Sixty patients were screened; fifty-four patients were eli-
gible to participate in the study and were randomly
assigned to omega-3 and placebo. Forty-one patients
completed the 6 week trial and 13 were dropped out
during the study (see Figure 1).
There was no statistically significant difference in
demographic data at baseline between the two groups
(Table 1). The distribution of other medications that
participants received during this trial did not differ be-
tween the 2 groups (Table 2). There were no statistically0 Patients screened
54 Randomized
-3 27 Assigned to Placebo
21 Completed Trial
6 Drop outs 
2 due to changing 
nzapine to risperidone* 
1 due to changing 
zapine to haloperidol * 
ue to poor compliance‡
olesterol above their respective goals. Non-HDL-C treatment goals are
dult Treatment Panel (ATP) III criteria [15]. Patients were categorized
b) not having CHD but having more than 2 risk factors, or c) not
h of the above categories if non-HDL-C is greater than 130 mg/dl,
liance and discontinuation of psychiatric medications. *Treating
nse.
Table 1 Demographic characteristic of patients
Omega 3 Placebo P Value
N= 20 N=21






Male 14 17 0.484
Female 6 4
Diagnosis
Bipolar I disorder 16 13 0.328
Schizophrenia 3 4
Schizoaffective disorder 1 4
Lifetime duration of illness
(months) (mean± SD)
27.20 ± 21.29 34.28 ±32.27 0.414
This table has been reproduced from our earlier paper [37] with permission
from Iranian Journal of Psychiatry.
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of outcome variables, except for fibrinogen level
(p = 0.034).
At the end point, mean daily dosage of olanzapine
was 13.00 ± 4.97 mg in the omega-3 and 12.85 ± 4.35 mg
in the placebo group (p = 0.922). VPA mean dosage in
omega-3 and placebo group were 749.00 ±189.73 andTable 2 Other medications received by participants
Medication Number (%) of Participants Placebo
Omega 3
Benzodiazepines
Clonazepam 14 (70) 14 (66.6)
Lorazepam 2 (10) 1 (4.76)
Chlordiazepoxide - 1 (4.76)
Typical Antipsychotics
Haloperidol 12 (60) 13 (61.9)
Chlorpromazine 6 (30) 5 (23.8)
Trifluoperazine - 1 (4.76)
Flupenthixol Decanoate 1 (5) 1 (4.76)
Atypical Antipsychotics
Risperidone 2 (10) 2 (9.5)
Other
Biperiden 12 (60) 13 (61.9)
Promethazine 2 (10) 2 (9.5)
Hydroxyzine - 1 (4.76)
Propranolol 4 (20) 5 (23.8)
Trazodone - 1 (4.76)
Ranitidine 1 (5) -
Omeprazole - 1 (4.76)
This table has been reproduced from our earlier paper [37] with permission
from Iranian Journal of Psychiatry.608.33 ± 235.32 mg (p = 0.170), respectively. On the
other hand, Li mean dosage in omega-3 and placebo
group were 1057.50 ± 288.20 and 1150.00 ± 300.00 mg
(p = 0.502), respectively.
At the end of this trial, the following observations
were noted. Mean weight, BMI and WC increased sig-
nificantly in both groups. There were no statistically sig-
nificant changes in systolic and diastolic BP within each
group. TC, LDL and non-HDL-C increased significantly
in both omega-3 and placebo groups. There was no sig-
nificant change in TG in any of the groups. HDL did not
change in omega-3 group but significantly increased in
the placebo group. Lp (a) did not significantly change in
the omega-3 group but significantly increased in the
group receiving placebo added to their regimen of olan-
zapine with Li or VPA. Additionally, a significant inter-
group effect was noted for Lp(a). Fibrinogen levels sig-
nificantly decreased in omega-3 group but its decrease
in placebo group was not statistically significant. There
was no statistically significant change in CRP-hs level
within each group (Table 3). Generally, omega-3 was
well tolerated by patients in this study. Mild fishy odor
was the only complaint that was expressed by one of the
participants.
Discussion
In this study, we evaluated the probable benefits of diet-
ary dose of omega-3 fatty acids on some traditional and
non-traditional cardiovascular risk factors, when added
at the beginning of SGAs and mood stabilizers before
the establishment of the metabolic side effects.
In this study, we did not observe a change in BP. Fish
oil (containing omega-3) supplementation for a median
duration of eight weeks has been shown to lower systolic
and diastolic blood pressures [9]. BP reduction pattern
of fish oils is also shown to be linear at dietary doses
(EPA plus DHA <1 g/day) and reaches plateaus at higher
than the dietary doses [16]. This effect is also claimed
to be less pronounced in healthy adults younger than
45 years-old [9,16] and may take a longer time to take
place [16]. Thus, the unchanged BP in this study may be
attributed to the younger age of the participants and the
short duration of trial.
Omega-3 fatty acids did not favorably affect LDL and
TC levels in our study; however, a trend toward lower
TC increment in the omega-3 group (15.6 mg/dl) than
that in placebo group (28.43 mg/dl) may suggest that
omega-3 may prevent increases in TC levels. Studies
have shown that omega-3 fatty acids can decrease small
dense LDL, a highly atherogenic form of LDL [17]. Thus,
it is suggested to measure this form of LDL when study-
ing effects of omega-3 on cholesterol levels.
With regard to HDL, McKenney and Sica reported
that omega-3 fatty acids can only modestly increase this
Table 3 Study Measures at baseline and at the end point
Variables Omega 3 P* Placebo P* Group effect comparison
Baseline End point Baseline End point F P**
Mean(SD) Mean(SD) Mean(SD) Mean(SD)
BW† (kg) 70.68 ± 13.35 75.03 ± 13.98 0 < 001 74.27 ± 11.17 78.35 ± 14.55 0.008 0.025 0.875
BMI (kg/m2) 24.43 ± 3.03 25.95 ± 3.27 0 < 001 24.95 ± 3.63 26.28 ± 4.66 0.004 0.137 0.714
WC (cm) 83.59 ± 8.88 86.84 ± 8.94 0.007 88.13 ± 13.23 91.02 ± 13.48 0.003 0.071 0.791
SBP (mmHg) 119.50 ± 9.98 115.50 ± 11.45 0.088 113.80± 9.34 115.50 ± 8.21 0.560 3.011 0.091
TC (mg/dl) 172.30 ± 34.94 187.90 ± 34.55 0.023 177.66± 37.78 206.09 ± 52.71 0.001 1.69 0.201
LDL (mg/dl) 86.40 ± 22.16 100.30 ± 17.93 0.004 91.09 ± 24.49 104.14 ± 30.78 0.004 0.021 0.885
HDL (mg/dl) 35.45 ± 9.04 35.45 ± 8.78 1.000 37.23 ± 11.30 39.23 ± 10.21 0.021 0.868 0.357
Non-HDL-C (mg/dl) 136.85 ± 30.63 152.45 ± 30.29 0.013 141.28± 34.73 166.85 ± 50.83 0.001 1.387 0.246
TG (mg/dl) 162.90 ± 72.51 165.95 ± 68.79 0.825 168.90± 71.83 171.76 ± 88.54 0.865 0.000 0.993
Lipo (a) (mg/dl) 46.64 ± 43.52 43.85 ± 29.81 0.623 45.35 ± 38.21 65.47 ± 57.52 0.042 4.507 0.040
Fibrinigen (mg/dl) 321.95 ± 56.41 283.80 ± 71.62 0.041 286.23± 47.34 282.57 ± 63.83 0.787 2.497 0.122
CRP-hs (mg/dl) 4.33 ± 4.198 4.11 ± 8.46 0.969 3.10 ± 3.17 3.49 ± 3.03 0.634 0.017 0.897
† BW, body weight; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; Non-HDL-C, non high-density lipoprotein-cholesterol; TG, triglyceride; Lipo (a), lipoprotein Lp(a); CRP-hs, c-reactive protein, high sensitivity.
* P-values are given for the comparison of before-after changes in each group using paired-samples t test.
** P-values are given for comparison of end point changes from baseline using within-subjects effects of Repeated Measure ANOVA considering interaction of
groups.
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changed values of HDL in our study. Contrary to our
expectations, HDL levels were increased significantly in
the placebo group that may be related to the fact that
our sample size was not sufficient to detect more pro-
nounced effects for some of the outcome variables in-
cluding HDL.
Despite our hypothesis, omega-3 fatty acids did not re-
duce TG levels in our study. Some studies have shown
that TG lowering effects of omega-3 fatty acids occur
within months to years and with a greater effect in
patients with higher baseline TG levels [16,17]. In
addition, effect of omega-3 on lowering TG concentra-
tion appears to be linear; omega-3 in doses of 3-4 g/day
have greater effect compared with doses <1g/day [16].
Therefore, the reason that TG levels were not reduced
in our study may be due to the fact that psychiatric
patients without important medical problems were
included, lower EPA and DHA doses were utilized, base-
line TG levels were not considered in the high range and
this trial was performed in a relatively short duration of
time.
Current guidelines identify non-HDL-C as a secondary
target of therapy in patients with TG ≥ 200 mg/dl after
achieving LDL goals [15]. Non-HDL-C increased signifi-
cantly in each study group; however, no difference was
noted between the two groups. Interestingly, when
evaluating patients whose TG levels were above 200 mg/
dl at the end of the present trial, increase in non-HDL-
C, requiring treatment, was identified in 2.4% of partici-
pants in the omega-3 group versus 14.6% in the placebogroup. This is while, at the beginning of the study, we
excluded patients with non-HDL-C levels requiring
treatment according to NCEP ATP III guidelines [15],
from entering the study. Thus, the above finding may
suggest a promising role for dietary doses of omega-3 to
prevent increases of non-HDL-C concentrations above
target levels in patients receiving psychiatric medications
with metabolic side effects.
Along with elevated LDL cholesterol, elevated Lp(a) is
considered to promote atherosclerosis [19]. Lp(a) serum
levels are primarily, genetically controlled, however, its
levels may also be affected by some exogenous factors
[20]. Long term treatment with anti-epileptic drugs,
specifically VPA is shown to increase Lp(a) levels in
patients with epilepsy [20–23]. Currently, medication
effects on Lp(a) are limited. According to the results of
our study, omega-3 supplementation prevented Lp(a)
elevation due to therapy. In line with our results, a fa-
vorable effect of omega-3 on decreasing Lp(a) serum
levels was previously demonstrated in hypertensive and
coronary artery disease patients [24,25].
MetS is a procoagulant state with elevated fibrinogen
level as a contributor. Elevated fibrinogen has been
observed in patients with obesity [26]. Additionally,
increased fibrinogen plasma levels are considered a risk
factor for major CVDs including coronary heart disease
and stroke [27]. Baptista and his colleagues hypothesized
that olanzapine increases fibrinogen levels, leading to a
procoagulant state [26]. Another study demonstrated
elevated levels of fibrinogen after 12 weeks of olanzapine
administration in patients with schizophrenia [28]. In
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brinogen levels [23,29,30], indicating impaired hepatic
synthetic function [29]. The above studies did not assess
the relevance of decreased fibrinogen levels to CVD risk.
However, VPA may still lead to atherosclerosis and
thrombosis despite decreased fibrinogen levels [30]. In
our study fibrinogen plasma levels did not change in the
group assigned to placebo. Even although the effects of
most of the other medications on this parameter is yet
unclear, the above finding may reflect a probable com-
bined effect of olanzapine and valproate on fibrinogen
plasma levels. Interestingly, in the group assigned to
omega-3, fibrinogen levels decreased significantly by
38.15 mg/dl (from 321.95 mg/dl to 283.80 mg/dl). The
normal range of fibrinogen level is 200-400 mg/dl [31].
Whether this decrease in fibrinogen level corresponds to
CVD reduction, remains to be elucidated.
Evidence supports inflammatory processes contribut-
ing to atherogenesis. Centers for Disease Control and
Prevention and the American Heart Association have
defined values of CRP-hs <1, 1-3 and > 3 mg/dl as low,
average and high risks to develop CVD, respectively
[32]. It should be noted that elevated levels of CRP has
been observed in patients with BD and schizophrenia
which may suggest an inflammatory component in these
psychiatric illnesses [33,34]. At baseline we observed
CRP-hs values of 4.33 and 3.1 mg/dl in the omega-3 and
placebo groups, respectively; these values remained ele-
vated throughout the study period. The above observa-
tion suggests an inflammatory process occurring in
psychiatric patients and remaining beyond the acute
phase of the involved illnesses. This is consistent with
Dickerson et al. report on elevated levels of CRP in out-
patients with a relatively long duration of BD. Our
results also showed that omega-3 fatty acids did not have
any significant effect on CRP-hs levels. In general, con-
trolled trials have not detected significant effects of
omega-3 supplementation on CRP-hs levels [35].
Despite the suggested protective role of omega-3
against abdominal obesity [36], this supplement could
not lessen increases in weight and WC in our study
patients. After 6 weeks, our participants significantly
gained a mean of 4.35 kg in the omega-3 group and
4.07 kg in the placebo group. Few studies have reported
the extent to which each specific combination therapies
of Li or VPA plus olanzapine increase weight. This study
was not designed to assess weight changes related to
various combination therapies or to any of these agents
alone. However, our results were similar to those
reported by Kim et al. who reported weight gain of
3.8 ± 2.9 kg with olanzapine plus VPA and 3.3 ± 3.1 kg
with olanzapine plus Li. Kim et al. also found that olan-
zapine monotherapy resulted in 1.6 ± 3.5 kg increase in
weight after 4 weeks in patients with BD [6].It should be emphasized that the short duration of our
study set limit to observe more profound effects. Add-
itionally, even though the assessment of omega-3 effects
was aimed to be accomplished in a realistic setting, re-
ceiving combination of olanzapine with a mood
stabilizer by patients might have influenced the results
of the present study. Another limitation that could influ-
ence our study was the fact that even though patients
were asked not to change their regular diet during the
study, they were not strictly controlled for their diet cal-
ories taken and activity levels.
In conclusion the addition of dietary doses of omega-3
fatty acid supplements per day at the commencement of
olanzapine combination with either Li or VPA may not
prevent or modulate early anthropometric and lipid pro-
file deterioration. However, this study noted that Lp(a)
level was not elevated and fibrinogen level was decreased
in patients receiving omega-3 fatty acids for six weeks. A
trend toward smaller increases in TC levels and the abil-
ity to prevent non-HDL-C exceeding its target in
patients with TG levels above 200 mg/dl supports some
cardiovascular benefit of low dose omega-3.Conclusion
This study suggests that short-term use of omega-3 sup-
plementation added at the beginning of a combined regi-
men of olanzapine and mood stabilizer may only benefit
by modulating some non-traditional cardiovascular risk
factors. Trials in longer periods of time and with larger
number of patients are recommended to further evaluate
the effects of omega-3 supplements on preventing car-
diovascular risk factors.
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